Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01199718Phase 1Unknown

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT00891280Phase 1Unknown

Dose-escalation Study of Oral CX-4945

Role: lead

NCT00780663Phase 2Completed

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Role: lead

NCT00955786Phase 1Completed

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Role: lead

NCT00955292Phase 1Terminated

Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Role: lead

NCT00485966Phase 2Withdrawn

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Role: lead

All 6 trials loaded